Kenny Walter

The treatment is approved as either a monotherapy or an adjunctive therapy with either lithium or valproate.

Weight loss could be beneficial for NASH and NAFLD patients.

The treatment represents the first approved treatment that directly targets sickle hemoglobin polymerization.

TARGET-NASH as now expanded into European centers.

Dr. Carl V. Crawford led a panel in discussing treatments in the pipeline for CDI.

Treatment failure occurred in 10% of the intensive treatment group compared to 28% in the standard treatment group

The treatment resulted in a significant reduction of proteinuria from baseline in 34% of trial participants.

The approval represents the first ever treatment for the disease in patients aged 2 years and older.

Eli Lilly and Company is expected to apply for a Biologics License Application in the first half of 2022.

The enrollment distribution was consistent by ethnicity over the course of 18 years, with no change in diversity over time despite there being an increase in the UK in the minority population.

Biologics account for significant healthcare-related costs for patients with either ulcerative colitis or Crohn’s disease.

Patients with SCD were not at an increased risk of death or disease complications.

High dose vitamin D supplementation has been linked to fewer pain days and higher physical activity scores for patients with chronic pain.

Moderate weekly consumption of beer was marginally associated with a reduction in the risk of Crohn’s disease.

Patients with sickle cell disease often suffer from acute kidney injuries and chronic kidney disease.

At least 3 companies have presented later phase data on live microbiota therapies for treating recurrent C difficile infections in 2021.

The US recommended HBV vaccines to be part of the infant immunization plan in 1991.

The rigidity of hospital settings and a lack of awareness prevents better hepatitis C virus diagnoses in the homeless population.

Bincy Abraham, MD, led the State of Science program on C difficile infections.

The treatment also has potential in Crohn's disease and rheumatoid arthritis.

Several different cardiovascular symptoms have presented in patients with COVID-19.

Circadian disruption presented across a variety of high-risk, prodromal, and syndromic psychiatric disorders.

COVID-19 mitigation measures resulted in a historically low influenza season.

The State of the Science events allows experts to come together to update on recent research for CDI.

Obesity is a risk factor for both obstructed sleep apnea and IHH.

Nearly half of patients not in clinical remission achieved de novo clinical remission after 1 year in the maintenance study.

Authors suggest children with uncontrolled asthma should be considered for priority for COVID-19 vaccination.

Copy number variations were broadly associated with an increased risk of autism spectrum disorder and ADHD.

The recombinant vaccine resulted in higher rates of seroprotection in all subjects, particularly those 45 years and older.

IBD patients also were more likely to have bloody diarrhea and abdominal pain.